Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash & Equivalents (2017 - 2025)

Inspire Medical Systems (INSP) has disclosed Cash & Equivalents for 9 consecutive years, with $104.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 30.19% to $104.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.8 million through Dec 2025, down 30.19% year-over-year, with the annual reading at $104.8 million for FY2025, 30.19% down from the prior year.
  • Cash & Equivalents hit $104.8 million in Q4 2025 for Inspire Medical Systems, down from $112.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $467.1 million in Q2 2023 to a low of $53.9 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $224.9 million across 5 years, with a median of $186.1 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 150.34% in 2023 and later tumbled 69.28% in 2025.
  • Year by year, Cash & Equivalents stood at $214.5 million in 2021, then surged by 105.9% to $441.6 million in 2022, then tumbled by 57.98% to $185.5 million in 2023, then decreased by 19.07% to $150.2 million in 2024, then crashed by 30.19% to $104.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for INSP at $104.8 million in Q4 2025, $112.8 million in Q3 2025, and $106.9 million in Q2 2025.